At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Gamma-Secretase Inhibitor RO4929097 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of RO4929097 (IND 109291) in Patients With Advanced Renal Cell Carcinoma (RCC, NOS 10038415) That Has Progressed After VEGF/VEGFR Directed Therapy
In Brief
A Phase 2 clinical trial evaluating Gamma-Secretase Inhibitor RO4929097 and Laboratory Biomarker Analysis for Clear Cell Renal Cell Carcinoma and 2 related conditions. Completed, enrolled 12 participants across 4 sites.
Detailed Summary
The purpose of this study is to evaluate the activity of RO4929097 in renal cell carcinoma patients that have failed therapy with VEGF/VEGFR directed agents.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedJun 2010
Primary CompletionMay 2012
Study CompletionDec 2013
TodayJul 2026
First PostedJun 10, 2010
Enrollment StartJun 1, 2010
Primary CompletionMay 1, 2012
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 16.1 years ago
Interventions
Gamma-Secretase Inhibitor RO4929097drug
Given PO
Laboratory Biomarker Analysisother
Correlative studies